Mark D. Bogost
コンサルタント
Expertise:
Mark is a consultant at EVERSANA MANAGEMENT CONSULTING with a background in business development, neurophysiology and data modeling.
Before joining EVERSANA, Mark obtained more than four years of research experience investigating the biological, computational and medical perspectives of brain disorders. Following academia, Mark moved into business development and project management positions within startup and healthcare environments, leading the development of novel medical devices as well as neuroinformatic projects.
Mark is an MBA graduate from the University of Southern California, where he focused on business analytics and general management. In addition to his business education, Mark earned a master of science in physiology and a bachelor’s degree in biology from the University of Oregon and the University of California at Davis, respectively.
Articles by Mark D. Bogost
Breaking through Barriers: Critical Success Factors for Launching Products with Breakthrough Therapy Designation
The FDA’s Breakthrough Therapy Designation (BTD) expedites patient access to innovative new treatments. While speeding up these processes can get new drugs to patients in need faster than they normally would through standard tracks, limited clinical evidence at launch and a compressed launch timeline can present stumbling blocks and uncertainties for commercialization teams tackling launch strategy, planning and execution. A differentiated product will contribute to broader adoption in the marketplace, but that is not the sole factor determining its success. Launch teams must understand that they can control and shape the product’s trajectory. Download the white paper to learn more about the implications of launching BTD products and some critical […]